Immunomodulation with enterotoxins for the generation of secretory immunity or tolerance: applications for oral infections.
about
Structure–activity correlations of variant forms of the B pentamer ofEscherichia colitype II heat-labile enterotoxin LT-IIb with Toll-like receptor 2 bindingDiarrheagenic Escherichia coli.Prolonged protection against Intranasal challenge with influenza virus following systemic immunization or combinations of mucosal and systemic immunizations with a heat-labile toxin mutant.Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal deliveryCholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins.Enhanced antigen uptake by dendritic cells induced by the B pentamer of the type II heat-labile enterotoxin LT-IIa requires engagement of TLR2.Binding to gangliosides containing N-acetylneuraminic acid is sufficient to mediate the immunomodulatory properties of the nontoxic mucosal adjuvant LT-IIb(T13I)Functional diversity of heat-labile toxins (LT) produced by enterotoxigenic Escherichia coli: differential enzymatic and immunological activities of LT1 (hLT) AND LT4 (pLT)Enhancement of immune responses by an attenuated Salmonella enterica serovar Typhimurium strain secreting an Escherichia coli heat-labile enterotoxin B subunit protein as an adjuvant for a live Salmonella vaccine candidate.Cholera toxin impairs the differentiation of monocytes into dendritic cells, inducing professional antigen-presenting myeloid cells.Characterization of antigen-presenting cells induced by intragastric immunization with recombinant chimeric immunogens constructed from Streptococcus mutans AgI/II and type I or type II heat-labile enterotoxinsDistinctive immunomodulatory and inflammatory properties of the Escherichia coli type II heat-labile enterotoxin LT-IIa and its B pentamer following intradermal administration.Mucosal immunization with a Staphylococcus aureus IsdA-cholera toxin A2/B chimera induces antigen-specific Th2-type responses in mice.TLR2-dependent modulation of dendritic cells by LT-IIa-B5, a novel mucosal adjuvant derived from a type II heat-labile enterotoxin.Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants.In vitro induction of immunoglobulin A (IgA)- and IgM-secreting plasma blasts by cholera toxin depends on T-cell help and is mediated by CD154 up-regulation and inhibition of gamma interferon synthesisAntibody against recombinant heat labile enterotoxin B subunit (rLTB) could block LT binding to ganglioside M1 receptorThe Divergent CD8+ T Cell Adjuvant Properties of LT-IIb and LT-IIc, Two Type II Heat-Labile Enterotoxins, Are Conferred by Their Ganglioside-Binding B Subunits.Gonococcal transferrin binding protein chimeras induce bactericidal and growth inhibitory antibodies in miceNanoemulsion nasal adjuvant W₈₀5EC induces dendritic cell engulfment of antigen-primed epithelial cells.Cholera toxin and Escherichia coli heat-labile enterotoxin, but not their nontoxic counterparts, improve the antigen-presenting cell function of human B lymphocytesAnthrax edema toxin induces maturation of dendritic cells and enhances chemotaxis towards macrophage inflammatory protein 3beta.In vivo and in vitro adjuvant activities of the B subunit of Type IIb heat-labile enterotoxin (LT-IIb-B5) from Escherichia coli.Toll gates to periodontal host modulation and vaccine therapyIdentification and characterization of intestinal antigen-presenting cells involved in uptake and processing of a nontoxic recombinant chimeric mucosal immunogen based on cholera toxin using imaging flow cytometry.Heat-labile enterotoxins as adjuvants or anti-inflammatory agents.Type II heat-labile enterotoxins: structure, function, and immunomodulatory properties.Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles.Mapping of a microbial protein domain involved in binding and activation of the TLR2/TLR1 heterodimer.Generation of a safe Salmonella Gallinarum vaccine candidate that secretes an adjuvant protein with immunogenicity and protective efficacy against fowl typhoid.Analysis and application of a neutralizing linear epitope on liable toxin B of enterotoxin Escherichia coli.Purification and characterization of Yersinia enterocolitica and Yersinia pestis LcrV-cholera toxin A(2)/B chimeras.Adjuvant-Mediated Epitope Specificity and Enhanced Neutralizing Activity of Antibodies Targeting Dengue Virus Envelope ProteinGanglioside GD1a is an essential coreceptor for Toll-like receptor 2 signaling in response to the B subunit of type IIb enterotoxin.Immunogenicity of a Staphylococcus aureus-cholera toxin A2/B vaccine for bovine mastitis.An LTB-entrapped protein in PLGA nanoparticles preserves against enterotoxin of enterotoxigenic Escherichia coli.
P2860
Q27675134-F8454483-0DB9-47A3-BDAE-11A0B8A7CB0FQ28078385-FC1244B7-C2E5-4937-A4AA-E79009508FE4Q30374752-B16563E7-CF40-43E0-85B7-9583CBDA482CQ33584872-46DEEEAE-8F3C-4C64-9BF9-684139A8A88AQ33768109-FC4B2CA7-2EDA-47C2-8D7A-1EF57BDA0676Q33820591-00FE936D-57B7-4669-8530-8627C673A853Q33909162-8E4C062F-FD4A-46BB-BAAE-4848920ADCA1Q34568384-BD7F35F2-4FF4-47A4-82EB-D179E37BA172Q34738751-884C3EFD-96FA-4053-88B1-7F1CAD1B25D9Q34739851-7437F849-5C20-4B0F-AA82-0AD0C20D9B6CQ34972133-26DAF9A8-C990-49C7-B851-FFC3AE8DD2D2Q35138744-990EA43C-AE3F-47B0-9095-3EF8A71EC38DQ35191220-CF74A385-D32D-4556-97B1-6A11383B36B3Q35505233-D46587BF-6B16-4574-824B-659F50FB5CF6Q35689341-4B8C7504-89F6-4AC4-B718-2D2D94CC95D1Q35689492-025E2D47-B915-4E3F-A9CA-4F19BAF988B6Q35757910-84975BAE-A927-4DDB-A52C-85334B7E1E09Q35840727-22D60705-E340-4AF8-AEA0-DD580FBA5138Q36427185-AE5A9BED-F83A-46B6-923D-A8E38D7E4553Q36565552-8392C54E-C07E-4039-97BA-B3907D7D05F8Q37191283-777A0CD9-440D-4D58-B0B8-1B5AF3A16CFFQ37191376-48C1FE8F-0BD0-4AC6-975F-C2C339630046Q37238638-A6F492E2-EC9F-4C47-8361-7CDED5BDC148Q37416211-435BA467-77E3-480A-BA44-605CD6B4D217Q37544969-3D54D798-5D75-42EA-9F77-7A6F01547EBBQ37749719-38714662-C6EF-4DA1-B6A1-A1B467A58769Q38058640-BDA1DD06-46F4-40E4-91EB-8CBBBB524B9DQ38335733-FE87FCCA-2329-4FD7-8D36-00C819C1DDCEQ39881046-B6969C3A-D9B5-49E9-A1CB-48E4A78DCA68Q40212185-E9040077-5E0B-46FC-9569-DA0C53E4BCBBQ41400988-7B8F0C10-3771-4ECF-871D-AC1835BC2952Q41434206-F78AD46D-79DD-49A5-A01B-DC709D3FF75BQ41921198-2BC1B886-E634-4B8D-9C0F-44720963A3A2Q51800575-0C82C1BE-C8B2-44F1-9EB1-FE410C284E8DQ54217815-6634E404-7B99-4C29-8CFD-935EA975B15EQ55386075-E327DD5F-C719-46B6-899D-6826228C83EF
P2860
Immunomodulation with enterotoxins for the generation of secretory immunity or tolerance: applications for oral infections.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Immunomodulation with enteroto ...... lications for oral infections.
@ast
Immunomodulation with enteroto ...... lications for oral infections.
@en
type
label
Immunomodulation with enteroto ...... lications for oral infections.
@ast
Immunomodulation with enteroto ...... lications for oral infections.
@en
prefLabel
Immunomodulation with enteroto ...... lications for oral infections.
@ast
Immunomodulation with enteroto ...... lications for oral infections.
@en
P2093
P2860
P1476
Immunomodulation with enteroto ...... lications for oral infections.
@en
P2093
C M Gockel
G Hajishengallis
M W Russell
T D Connell
P2860
P304
P356
10.1177/154405910508401205
P407
P577
2005-12-01T00:00:00Z